Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Niagen Bioscience (NAGE) EBITDA Margin (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed EBITDA Margin for 15 consecutive years, with 12.07% as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA Margin fell 1234.0% to 12.07% in Q4 2025 year-over-year; TTM through Dec 2025 was 12.58%, a 482.0% increase, with the full-year FY2025 number at 12.58%, up 482.0% from a year prior.
  • EBITDA Margin was 12.07% for Q4 2025 at Niagen Bioscience, down from 12.46% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 24.42% in Q4 2024 to a low of 51.08% in Q3 2021.
  • A 5-year average of 11.02% and a median of 6.38% in 2022 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: plummeted -2149bps in 2021, then soared 3607bps in 2023.
  • Niagen Bioscience's EBITDA Margin stood at 29.93% in 2021, then soared by 77bps to 6.88% in 2022, then skyrocketed by 88bps to 0.79% in 2023, then surged by 3180bps to 24.42% in 2024, then tumbled by -51bps to 12.07% in 2025.
  • Per Business Quant, the three most recent readings for NAGE's EBITDA Margin are 12.07% (Q4 2025), 12.46% (Q3 2025), and 10.24% (Q2 2025).